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Background. The present research aimed to investigate the efﬁcacy of a multifaceted intervention that included motiv-
ational interviewing (MI) and psychoeducation in improving medication adherence (MA) among patients with bipolar
disorder (BD).
Method. A multicenter, cluster randomized, observer-blind, controlled, parallel-group trial was conducted in ten aca-
demic centers in Iran. Patients with BD were randomly assigned to the experimental group (EXP; n = 136) or the
usual care group (UC; n = 134). The EXP group received ﬁve sessions of MI and psychoeducation together with their fam-
ily members. The primary outcome measure was changes in scores on the Medication Adherence Rating Scale from base-
line to 6 months post-intervention. Other outcome measures included serum levels of mood stabilizers, clinical
symptoms, quality of life, as well as measures of intention, beliefs about medicine, perceived behavioral control, auto-
maticity, action and coping planning, and adverse reactions.
Results. Medication adherence improved over time in both groups, but patients in the EXP group improved more (base-
line score: 6.03; score at the sixth month: 9.55) than patients in the UC group (baseline score: 6.17; score at the sixth
month: 6.67). In addition, patients in the EXP group showed greater improvement than patients in the UC group in
almost all secondary outcomes 6 months following the intervention.
Conclusions. Multifaceted interventions that include motivational-interviewing and psychoeducation can signiﬁcantly
improve MA and clinical and functional outcomes in patients with BD.
Trial Registration Number: The trial was registered with theClinicalTrials.gov database (NCT02241863) https://clinical-
trials.gov/ct2/show/NCT02241863
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Introduction
Bipolar disorder (BD) causes signiﬁcant disability in
personal and social domains, and with a prevalence
of 1–2% (Merikangas et al. 2007), it imposes a huge bur-
den on society. According to a recent meta-analysis,
patients with BD spend more than 40% of their time
ill (Forte et al. 2015). Despite the fact that it is possible
to control the symptoms of BD using medication, low
levels of adherence is a substantial problem and have
been reported in up to 50% of cases (Lacro et al.
2002; Lingam & Scott, 2002; Scott & Pope, 2002a, b;
Geddes & Miklowitz, 2013). Patients with BD show a
much lower rate of routinely and consciously taking
prescribed medicines (35%) than patients with, for
example, schizophrenia (50–60%). Consequently,
patients with BD tend to have poorer health outcomes,
including lower levels of daily functioning, psycho-
logical health, and quality of life (QoL) (Dean et al.
2004; IsHak et al. 2012). Therefore, it is important to
develop interventions that can promote medication
adherence (MA).
Effective interventions are likely to be those that tar-
get modiﬁable determinants of non-adherence (Berk
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et al. 2004), such as beliefs and attitudes (Lingam &
Scott, 2002; Scott & Pope, 2002a; Berk et al. 2004). As
a result, a few studies (Bauer et al. 2006a, b; Cakir
et al. 2009; Javadpour et al. 2013) have designed
behavioral interventions (e.g. behavioral therapy, fam-
ily reliant treatments, psychosocial education, and
interpersonal therapies) in an effort to promote MA.
For example, Parsons et al. used behavioral therapy
to improve MA in HIV-positive people and found
reductions in substance abuse (although no signiﬁcant
change in MA, perhaps due to the relatively small sam-
ple (Folco et al. 2012). In another study on BD patients,
eight sessions of psychoeducation yielded better MA
and also QoL among participants in the intervention
group when followed up 2 years later (Javadpour
et al. 2013). Other interventions designed to promote
MA have focused on increasing communication
and support provided by family members to patients,
and this strategy is popular for the treatment of
mental disorders such as schizophrenia (Rollnick
et al. 2008).
However, previous studies that have addressed the
challenge of MA in patients with BD have been some-
what limited in their methods. To the best of our
knowledge, all previous studies have only used one
type of intervention (namely, psychoeducation) in add-
ition to usual care (Rouget & Aubry, 2007). The beneﬁ-
cial effects of psychoeducation for patients with BD
have been demonstrated on a number of different out-
comes, including MA, insight improvement, and a
reduction in symptoms relief for people with BD
(Rouget & Aubry, 2007; Bilderbeck et al. 2016;
Hidalgo-Mazzei et al. 2016; Kallestad et al. 2016).
Similar interventions have also been shown to reduce
the burden of care, as well as distress among family
members (Bermúdez-Ampudia et al. 2016; Hubbard
et al. 2016). Given that patients with BD can differ in
their responses to the same intervention (Culpepper,
2014), it is possible that a multifaceted intervention
that targets various reasons for non-adherence might
result in even better outcomes.
A second problem with the evidence-base to date is
that many (but not all) previous studies (Bauer et al.
2006b; Cakir et al. 2009; Javadpour et al. 2013) have pri-
marily used self-reported questionnaires to measure
MA. However, self-reported outcomes may be biased
by social desirability effects (e.g. patients with BD
may feel obligated to report that they have followed
the instructions of a health professional) and/or mem-
ory problems (e.g. patients with BD may not remember
whether they have taken their medication). Using
objective measures of adherence, such as serum levels
of mood stabilizers, can reduce the possibility of bias
and provide a more accurate estimate of the effect of
an intervention on MA.
The present research
Given the importance of developing interventions to
promote MA among people with BD and the limita-
tions of the current evidence, the present research
sought to develop a multifaceted intervention and
examine the effects of the intervention on self-report
and objective indices of MA, as well as secondary out-
comes that include potential mediators of treatment
effects. The intervention was centered around motiv-
ational interviewing (MI), a client-centered approach
that seeks to change attitudes and behavior (Lundahl
et al. 2013). Although originally developed for redu-
cing alcohol dependence, the use of MI has been rap-
idly expanded to other health-related domains.
Indeed, a meta-analysis of 48 studies has shown that
MI is an effective way to promote changes in behavior
across multiple healthcare domains such as diabetes,
obesity, smoking, and HIV treatment (Lundahl et al.
2013). In recent years, MI has also been used to
improve MA in conditions that require long-term com-
mitment to treatment such as schizophrenia and acute
coronary syndrome (Depp et al. 2007). Nevertheless,
there is scant evidence on the effect of MI in improving
MA in patients with BD.
In addition to MI, we also investigated the idea that
interventions might beneﬁt from including family
members, because family members are likely to sup-
port patients with BD in taking their medications
(Williams & Wright, 2014) especially in the East,
where culture substantially values the family relation-
ship (Tsai et al. 2015).
Despite the importance of MA (or lack thereof) in
patients with BD, a systematic review of studies testing
the efﬁcacy of interventions designed to improve MA
in BD found only ﬁve studies whose primary outcome
was adherence. A meta-analysis of 18 studies showed
an OR of 2.27 (95% CI 1.45–3.56) for improvement in
adherence in the intervention group compared with
control groups (MacDonald et al. 2016).To the best of
our knowledge, our study is the most comprehensive
study to date of a multifaceted intervention to improve
the adherence in patients with BD.
Methods
Design and study population
A multicenter, randomized, observer-blind, controlled,
parallel-group trial was conducted in ten academic
centers in Iran: Tehran (three centers), Qazvin,
Ahvaz, Semnan, Zanjan, Tabriz, Zahedan, and
Mashahd between September 2014 and October 2016.
Persian speaking patients were eligible if they: (1)
met the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) criteria for bipolar I or II
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disorders simultaneously conﬁrmed by the administra-
tion of Structured Clinical Interview (SCID); (2) were
18 years or older; (3) were being treated with a mood
stabilizer; and (4) were not attending weekly or
biweekly psychotherapy. Patients were excluded if
they: (1) had a DSM-IV-TR diagnosis of drug or alcohol
misuse disorders (ﬁve independent researchers admi-
nistered a semi-structured interview and a structured
interview based on DSM-IV-TR criteria for alcohol
abuse, alcohol dependence and also substance abuse
excluding nicotine); (2) showed evidence of severe
DSM-IV-TR borderline personality; (3) needed to
change the type and/or the dose of a mood stabilizer;
(4) were pregnant or planned to be pregnant in the
next year; (5) were unable and/or unwilling to provide
a written informed consent; (6) had any organic cere-
bral cause for BD (e.g. multiple sclerosis or stroke); or
(7) had an intellectual disability. Figure 1 shows the
ﬂow of participants through the trial, including the
number of patients excluded for the various reasons
detailed above.
All patients and their family members provided
informed consent before participating in the study.
The protocol was prepared in accordance with the
Ottawa Statement, the Helsinki Declaration and
Good Clinical Practice, and ethical review committees
at each of the sites approved the trial. The trial was
registered in the clinicaltrials.gov registry (https://clin-
icaltrials.gov/ct2/show/NCT02241863).
Intervention
A multifaceted intervention was developed in an effort
to improve MA and clinical outcomes. The interven-
tion included two components: (a) Psychoeducation
for the patients and their family members and (b)
Miller & Rollnick (2012). Detailed information on the
intervention is provided in the online Supplementary
Materials.
MI integrity/ﬁdelity
To assess treatment ﬁdelity, all sessions were recorded
and transcribed. Two trained research assistants reviewed
each recording in order to determine the proportionof the
intervention elements that were covered by the facilita-
tors. The Motivational Interview Treatment Integrity
(MITI) scale was used to assess the integrity of the MI in
the EXP group. Two separate aspects of treatmentﬁdelity
were taken into account: (i) Global variables (i.e. empathy,
evocation, collaboration, autonomy/support, and direc-
tion) and (ii) behavior counts (i.e. giving information, ask-
ing open-ended and closed-ended questions, providing
Fig. 1. Flow of participants through the trial.
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simple and complex reﬂections, and making other state-
ments categorized as MI adherent or not). Inter-rater
reliability was computed using intraclass correlation
coefﬁcients (ICCs) in a two-way mixed model with abso-
lute agreement. The ICCs were found to be adequate for
global measures, behavior counts, and summary scores
(ICCs ranged from 0.69 to 0.92, as reported in online
Supplementary Table S1).
Usual care
Patients in the usual care (UC) group received the
usual care that is provided to people with severe men-
tal illnesses in Iran, which is mainly based on pharma-
cological interventions and follow-up visits to address
and deal with adjustments to the dosage and/or nature
of medications and management of side effects. There
are no national guidelines for the provision of psycho-
social services such as occupational rehabilitation, sup-
ported employment, social skills education, and family
support. However, during last decade, there has been a
growing interest in providing these services, such that
informal psycho-education about social skills and com-
pliance with treatment may be provided on some
occasions.
Outcomes
The primary outcome measure was MA measured
using self-report and objective indices. Secondary out-
comes included measures of beliefs and psychosocial
health. All outcomes were measured three times (at
baseline before the intervention, and then 1 and 6
months after the intervention) using the measures
described below. Clinical status was assessed using
the Clinical Global Impressions-Bipolar-Severity of
Illness (CGI-BP-S; (Spearing et al. 1997) and the
Young Mania Rating Scale (YMRS; Young et al. 1978)
and the Montgomery Åsberg Depression Rating Scale
(MADRS; Montgomery & Asberg, 1979) were used to
assess manic and depressive symptoms, respectively.
The clinical measures were administrated by ﬁve psy-
chiatrists who were blinded to the treatment allocation.
Medication Adherence Rating Scale (MARS)
The MARS was used to measure the primary outcome
in the study; namely, MA. Patients were asked to rate
the extent to which ﬁve statements describing non-
adherent behaviors, such as forgetting to take medi-
cines or missing a dose, apply to them on a 5-point
Likert scale (1: Always to 5: Never), e.g. Do you ever for-
get to take your medication? (O’Carroll et al. 2011). The
MARS has been shown to be relatively unaffected by
social desirability effects (O’Carroll et al. 2011), and
the Persian translation of the MARS (Pakpour et al.
2014) demonstrates unidimensionality and high levels
of internal consistency (Cronbach’s α = 0.84).
Plasma level of mood stabilizer
The primary outcome of MA was also assessed using
objective indices. Speciﬁcally, plasma levels of mood
stabilizers were obtained from biochemistry laborator-
ies at each center, and levels of three mood stabilizers
were assayed: Lithium, Carbamazepine, and Sodium
valproate.
Beliefs about Medicines Questionnaire – Speciﬁc
(BMQ-speciﬁc)
The BMQ-speciﬁc (Horne et al. 1999) was used to
assess beliefs about medications prescribed for per-
sonal use and has been shown to be correlated to
adherence (Pakpour et al. 2015). The measure reﬂects
two domains (necessity and concerns) and each
domain is assessed using ﬁve items that patients are
asked to indicate their agreement with on a 5-point
Likert scale (from 1: strongly disagree to 5: strongly
agree). The necessity domain assesses patients’ beliefs
about the necessity of the medication (e.g. Without
my medicines I would be very ill), while the concerns
domain examines patients’ beliefs about the possible
adverse effects of the medication (e.g. Having to take
medicines worries me). Scores can range between 5 and
25, with higher scores indicating stronger beliefs
about the necessity of the medication or a higher
level of concern about taking the medicine, respect-
ively. The Persian version of the BMQ has promising
psychometric properties and has been used to assess
beliefs about medications among an Iranian sample
with diabetes (Aﬂakseir, 2012).
Intention
Patients’ intention to take their medication was mea-
sured using a questionnaire adapted from Pakpour
et al. (2014). Patients were asked to indicate their agree-
ment with ﬁve statements (e.g. I intend to take regular
medication in the future) on a 5-point Likert scale (1: com-
pletely disagree to 5: completely agree). Internal consist-
ency of the scale was adequate (Cronbach’s α = 0.91).
Self-monitoring
Self-monitoring was measured by three items (e.g.
During the last week, I have consistently monitored when
to take my medications, on a 5-point Likert scale from
not at all true (1) to exactly true (5) (Pakpour et al.
2015). Cronbach’s α for the scale was 0.89.
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Self-report Behavioral Automaticity Index (SRBAI)
The SRBAI comprises four items from Self-Report
Habit Index (Gardner et al. 2012), that measure the
extent to which relevant behaviors are performed auto-
matically (a key component of habit; Orbell &
Verplanken, 2010). Each item starts with the stem
Behavior X is something. . .and is followed by (1) I do
automatically; (2) I do without having to consciously
remember; (3) I do without thinking; and (4) I start doing
before I realize I am doing it (Gardner et al. 2012). All
items were rated on a 5-point Likert scale (1: disagree
to 5: agree).
Action and coping planning
Action planning was measured using four items: I have
made a detailed plan regarding when / where / how often /
how to take medication. Similarly, coping planning was
measured using four items: I have made a detailed plan
regarding. . . (1) what to do if something interferes; (2)
what to do if I forget to take my medication; (3) how to
motivate myself if I don’t feel like taking my medication;
and (4) how to prevent myself from being distracted. All
items measuring action planning and coping planning
were rated on a 5-point Likert scale (1: completely dis-
agree to 5: completely agree) and showed high levels of
internal consistency in the present research
(Cronbach’s α = 0.90).
Perceived behavioral control (PBC)
PBC was measured using four items on a 5-point
Likert scale (1: completely disagree to 5: completely
agree) that have proved internally consistent in the pre-
sent research (Cronbach’s α = 0.94). Sample items
include: For me to take regular medication in the future
is. . . and It is up to me to take regular medication. . .
Young Mania Rating Scale (YMRS)
The YMRS contains 11 items each describing a speciﬁc
mania syndrome. Clinicians were asked to rate how
severely the patients have experienced each syndrome
within the past 2 days. The items include elevated
mood, increased motor and activity-energy, sexual
interest, sleep, irritability, speech rate and amount, lan-
guage/thought disorder, thought content, disruptive/
aggressive behavior, appearance, and insight. All
items were rated from 0 (absent) to 4 (the highest
level), and four of the items (irritability, speech,
thought content, and disruptive/aggressive behavior)
were double-weighted (Young et al. 1978; McIntyre
et al. 2004) when computing the overall score.
Montgomery Åsberg Depression Rating Scale
(MADRS)
The MADRS contains 10 items designed to measure
indicators of depression (e.g. reduced appetite). The
MADRS is designed to be particularly sensitive to the
effects of treatment (such as antidepressants) among
people with mood disorders. Clinicians were asked
to respond to each of the items on a 7-point Likert
scale and total scores could range from 0 (no symp-
toms of depression) to 60 (highest level of depression
(Montgomery & Asberg, 1979).
Clinical Global Impressions-Bipolar-Severity of
Illness (CGI-BP-S)
The CGI-BP-S is modiﬁed from Clinical Global
Impressions Scale for speciﬁc use with patients with
BD. The CGI-BP-S comprised three measures to
which clinicians were asked to respond using a
7-point Likert scale. The measures evaluated: (1) The
severity of illness (Considering your total clinical experi-
ence with this particular population, how mentally ill is
the patient at this time?); (2) change from preceding
phase (Compared to the phase immediately preceding this
trial, how much has the patient changed?); (3) change
from worst phase (Compared to the patient’s worst
phase of illness prior to the current medication trial or dur-
ing the early titration phase, how much has the patients
changed?). A lower score on the CGI-BP-S suggests a
better condition (Spearing et al. 1997)
Quality of Life in Bipolar Disorder scale (QoL.BD)
The QoL.BD contains 12 items and is designed to cap-
ture patients’ subjective perceptions of BD-speciﬁc
QoL. Each item asks about a speciﬁc experience in
the past week (e.g. Felt physically well). Patients are
asked to respond on a 5-point Likert scale (1: strongly
agree to 5: strongly disagree), and a higher score repre-
sents a higher level of QoL (Michalak et al. 2010).
Adverse drug reaction (ADR)
Adverse reactions to the prescribed medications were
assessed using a questionnaire adapted from the clin-
ical monitoring form for mood disorders (Sachs et al.
2002). Patients were asked to indicate the severity of
nine side effects (e.g. tremor, dry mouth, etc.) on a
5-point Likert scale, ranging from none (0) to severe
(4). A total score was computed as the sum of the
severity of each side effect and could range from 0 to
36 with higher scores indicating more severe side
effects.
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Randomization and masking
In order to prevent contamination between the EXP
and UC groups, centers were used as unit of random-
ization rather than patients. Trained professionals at
each center (e.g. physicians and nurses) enrolled parti-
cipants. Centers were allocated in a 1:1 ratio to either
the EXP or UC groups by a computer-generated list
of random numbers. Five clusters were assigned to
the EXP group and ﬁve clusters to the UC group.
Figure 1 illustrates the allocation to condition and the
ﬂow of participants through the trial.
Across centers, 538 patients were referred to the trial:
43 declined to be screened for eligibility, 217 did not
meet screening criteria, and we lost contact with
eight. A total of 270 patients underwent baseline
assessment and 134 were randomized to the UC
group and 136 to the EXP group. As a result, each cen-
ter recruited an average of 26 patients. Assessors, psy-
chologists, and psychiatrists were blind to the
intervention status of the participants.
Sample size
The required sample size was calculated based on the
primary outcome measure (the MARS). It was esti-
mated that 132 patients would be needed in each con-
dition to detect an effect size of 1 point in the MARS,
with 85% power and a signiﬁcance level of 5%, assum-
ing an intracluster correlation coefﬁcient of 0.05, a
mean cluster size equal to 27, and that 10% of the
patients would likely be lost to follow up.
Statistical analysis
Due to the hierarchical nature of the data (i.e. patients
were nested within centers), we used multilevel linear
mixed modeling to investigate the efﬁcacy of the inter-
vention. Three levels of analysis – time, patients, and
centers – were estimated with a restricted iterative gen-
eralized least square (RIGLS) estimation. Therefore, for
each model, three ﬁxed effects were entered; an inter-
cept term, Time and condition (the UC group served
as the reference group).
To decompose the interaction between condition
and time, we compared the effects of condition at
each time point (i.e. 1 and 6 months after treatment)
on each dependent variable. The Benjamini and
Hochberg false discovery rate was used to adjust p
values for multiple comparisons. In addition, Krull
and MacKinnon’s three-step recommendations for con-
ducting mediation analyses were performed to identify
potential mediators of treatment effects (Krull &
MacKinnon, 1999). All tests were two sided with a
signiﬁcance level of <0.05 and analyses were
performed on an intent-to-treat basis using MLwiN
2.27 software.
Results
Randomization check
Table 1 summarizes the baseline and clinical character-
istics of the two groups. About 51% of the participants
in the UC group and 55% of the participants in the EXP
group were females and the mean age of the patients
was 41.2 (6.4) years in the UC group and 41.8 (8.4) in
the EXP group. The mean age of onset of BD was 24
years for both groups.
Effects of the intervention on the primary outcome:
medication adherence
Table 2 provides the descriptive statistics for all out-
come measures by condition and time. Tables 3 and
4 show the ﬁndings of three-level multiple linear
regression models examining the effect of the interven-
tion on outcomes. MA improved over time in both the
EXP and UC groups. However, scores on the MARS
indicated a greater improvement in MA among
patients in the EXP group: Mbaseline = 6.03 (S.D. = 2.56)
and Msix months = 9.55 (S.D. = 3.88); than among patients
in the UC group: Mbaseline = 6.17 (S.D. = 2.90) and Msix
months = 6.67 (S.D. = 2.93). In support of this idea, after
taking into account the study center and repeated
measurement over time, our multilevel mixed models
showed that patients in the EXP group had signiﬁ-
cantly higher MARS scores than did patients in the
UC group both one (B = 3.15; p < 0.001) and 6 months
(B = 3.20; p < 0.001) after the intervention (Table 3).
Analysis of the objective measures of MA; namely,
plasma level of mood stabilizers, indicated that
patients in the UC group had slightly decreased levels
of Lithium (baseline: 0.660 mmol/L; 6 month: 0.596
mmol/L), Carbamazepine (baseline: 5.580 mcg/mL; 6
month: 5.472 mcg/mL), and Sodium valproate (base-
line: 41.255 mcg/mL, 6 month: 41.001 mcg/mL) at 6
months post-intervention, suggesting that they may
not have been adhering to their medication regimen.
Incontrast, patients in theEXPgrouphad increased levels
of Lithium (baseline: 0.665 mmol/L; 6 month: 0.698
mmol/L), Carbamazepine (baseline: 5.596 mcg/mL; 6
month: 6.147 mcg/mL), and Sodium valproate (baseline:
40.094 mcg/mL; 6 month: 43.048 mcg/mL), supporting
the beneﬁcial effects of the intervention onMAsuggested
by the self-reportmeasure of adherence.After controlling
for study center and repeated measurement, patients in
the EXP group had signiﬁcantly higher plasma levels of
mood stabilizers than did patients in the UC group at 1
month (B = 0.108 for Lithium, 1.53 for Carbamazepine,
and 3.62 for Sodium valproate; p < 0.001), and 6 months
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(B = 0.178 for Lithium, 1.40 for Carbamazepine, and 5.28
for Sodium valproate; p < 0.001) post-intervention (see
online Supplementary Table S2).
Effects of the intervention on secondary outcomes
Almost all secondary outcomes improved over time in
the EXP group (see Table 2), and the ﬁndings of multiple
linear regression models (reported in Tables 3 and 4)
show that patients in theEXPgrouphad signiﬁcantlybet-
ter outcomes on all secondary measures 1 month and 6
months after the intervention, compared with patients
in the UC group, except for the measure of QoL at 1
month follow-up. Therefore, patients in the EXP group
had stronger intentions to take their medication, believe
that they had more control over so doing, that taking
their medication was more automatic, and were more
likely to form action and coping plans to promote MA.
There was also evidence of a decrease in clinical
symptoms among patients in the EXP group, relative
to patients in the UC group, as shown by signiﬁcant
effects of group on the YMRS (B =−5.32; p < 0.001),
CGI-BP-S (B =−0.528; p < 0.001), and MARDS (B =−
4.54; p < 0.001). Furthermore, the QoL of patients in
the EXP group improved signiﬁcantly more than
among patients in the UC group (B = 1.17; p = 0.025).
Mediation analyses
Online Supplementary Table S3 in the online
Supplementary Materials shows the direct and
mediated effects of group on MA and QoL. The effect
Table 1. Baseline and clinical characteristics of patients by condition
Mean (S.D.) or n (%)
Usual care (n = 136) Experimental (n = 134)
Age (year) 41.2 (6.4) 41.8(8.4)
Age at onset (year) 24.3 (6.1) 24.0 (5.9)
Sex
Male 67 (49.3%) 60 (44.8%)
Female 69 (50.7%) 74 (55.2%)
Education (year) 6.9 (3.4) 6.2 (4.0)
Duration of illness (year) 8.2 (5.6) 8.6 (5.3)
Monthly family income (US$)
High (>1000$) 26 (19.1%) 15 (11.2%)
Intermediate (500–1000$) 78 (57.4%) 92 (68.7%)
Low (<500$) 32 (23.5%) 27 (20.1%)
Bipolar disorder type
I 114 (83.8%) 110 (82.1%)
II 22 (16.2%) 24 (17.9%)
Living status
Living with partner 57 (41.9%) 52 (38.8%)
Single 79 (58.1%) 82 (61.2%)
Total number of episodes 8.3 (5.7) 8.5 (6.1)
Number of hospitalizations 2.1 (0.49) 2.2 (0.5)
Mood stabilizers (Yes)
Lithium 57 (41.9%) 56 (41.8%)
Carbamazepine 23 (16.9%) 19 (14.2%)
Sodium valproate 56 (41.2%) 59 (44.0%)
Antipsychotics (Yes) 34 (25.0%) 31 (23.1%)
Mood stabilizer monotherapy (Yes) 58 (42.6%) 54 (40.3%)
Drug dose at inclusion (mg)
Lithium 980.6 (212.8) 970.1 (200.1)
Carbamazepine 640 (173.2) 651 (171.9)
Sodium valproate 960 (141.9) 958 (134.6)
The total numbers of taking drugs 2.3 (1.0) 2.1 (1.2)
Body mass index (kg/m2) 26.8 (4.2) 25.9 (4.0)
Number of centers 5 5
Number of patients in each center 26.6 (3.1) 26.1 (3.4)
Note. S.D., standard deviation.
Promoting medication adherence among patients with bipolar disorder 7
https:/www.cambridge.org/core/terms. https://doi.org/10.1017/S003329171700109X
Downloaded from https:/www.cambridge.org/core. University of Colorado Boulder, on 28 Apr 2017 at 03:46:09, subject to the Cambridge Core terms of use, available at
of the intervention on self-reported MA were mediated
by changes in beliefs about medication (i.e. beliefs
about the necessity of taking the medication and con-
cern about the possible adverse effects of the medica-
tion), intention, self-monitoring, action planning, and
coping planning. In turn, MA mediated the effect of
the intervention on QoL.
We also examined whether self-reported MA (i.e.
scores on the MARS) mediated the effect of the
intervention on plasma levels of mood stabilizers.
The results of the mediation analysis indicated that
self-reported MA mediated the effect of the interven-
tion on improvements in plasma levels of mood stabi-
lizers. Speciﬁcally, scores on the MARS mediated the
effect of the intervention effect on improvements in
Serum Lithium levels at 1 month (B = 0.32; S.E. = 0.10;
p < 0.001) and 6 month (B = 0.42; S.E. = 0.07; p < 0.001)
follow-ups, improvements in Serum Carbamazepine
Table 2. Descriptive statistics for all outcome measures by condition and time
Variable Group
Mean (S.D.)/missing n
Baseline
One month
post-intervention
Six months
post-intervention
MARS UC 6.17 (2.90)/0 6.77 (2.85)/4 6.67 (2.93)/7
EXP 6.03 (2.56)/0 9.53 (3.84)/1 9.55 (3.88)/9
BMQ necessity UC 14.59 (2.31)/0 14.52 (2.20)/2 14.54 (3.01)/8
EXP 14.43 (2.29)/1 18.69 (2.49)/2 18.64 (2.48)/10
BMQ concerns UC 13.19 (3.97)/0 13.22 (3.92)/4 13.20 (4.13)/12
EXP 12.90 (3.31)/0 6.04 (3.80)/1 5.90 (3.75)/9
Perceived behavioral control UC 2.58 (0.92)/4 2.61 (0.95)/3 2.56 (0.97)/8
EXP 2.55 (0.90)/0 2.86 (1.06)/3 2.89 (1.13)/9
Intention UC 2.73 (0.65)/0 2.78 (0.69)/3 2.75 (0.71)/10
EXP 2.79 (0.75)/0 3.45 (1.12)/1 3.43 (1.14)/11
Self-monitoring UC 1.99 (0.42)/2 1.96 (0.52)/0 1.94 (0.43)/10
EXP 2.05 (0.53)/1 2.57 (1.03)/2 2.54 (1.01)/12
Action planning UC 1.91 (0.51)/0 1.89 (0.55)/3 1.86 (0.56)/9
EXP 1.90 (0.54)/1 2.64 (1.17)/4 2.66 (1.34)/9
Coping planning UC 1.67 (0.54)/0 1.64 (0.55)/4 1.65 (0.56)/9
EXP 1.65 (0.59)/1 2.40 (1.28)/5 2.39 (1.39)/9
SRBAI UC 1.88 (0.82)/0 1.87 (0.83)/2 1.79 (0.88)/8
EXP 1.90 (0.83)/0 2.14 (0.90)/4 2.20 (0.93)/11
QoL.BD UC 39.38 (9.18)/0 39.42 (9.26)/3 39.18 (9.27)/9
EXP 39.14 (11.34)/0 40.90 (11.63)/2 43.56 (12.37)/11
YMRS UC 15.57 (2.28)/0 15.59 (2.46)/3 15.61 (2.35)/7
EXP 15.32 (2.76)/0 12.23 (2.19)/1 10.04 (2.01)/9
CGI-BP-S UC 4.55 (0.65)/0 4.56 (0.61)/2 4.57 (0.47)/7
EXP 4.60 (0.75)/0 4.52 (0.51)/2 4.18 (0.43)/9
MADRS UC 21.82 (5.81)/0 21.37 (4.74)/2 21.28 (4.85)/7
EXP 22.21 (5.71)/0 17.08 (7.67)/3 17.13 (7.55)/9
ADR UC 10.03 (2.97)/3 10.00 (2.99)/6 9.98 (2.79)/9
EXP 9.94 (2.95)/4 10.09 (2.88)/3 10.15 (2.89)/12
Serum Lithium level (mmol/L) UC 0.66 (0.15)/0 0.601 (0.22)/2 0.596 (0.227)/4
EXP 0.67 (0.18)/0 0.694 (0.23)/1 0.698 (0.241)/2
Serum Carbamazepine level (mcg/mL) UC 5.58 (1.40)/0 5.496 (1.39)/2 5.472 (1.461)/1
EXP 5.60 (1.51)/0 5.948 (1.84)/1 6.147 (1.680)/3
Serum Sodium valproate level (mcg/mL) UC 41.26 (16.45)/0 41.09 (16.73)/2 41.001 (17.746)/4
EXP 40.90 (18.78)/0 42.55 (18.19)/0 43.048 (19.224)/3
Note. S.D., standard deviation; UC, usual care group; EXP, experimental group; BMQ, Beliefs about Medicines
Questionnaire; SRBAI, Self-report Behavioral Automaticity Index; MARS, Medication Adherence Rating Scale; QoL.BD,
Quality of Life in Bipolar Disorder scale; YMRS, Young Mania Rating Scale; CGI-BP-S, Clinical Global
Impressions-Bipolar-Severity of Illness; MADRS, Montgomery–Åsberg Depression Rating Scale; ADR, Adverse drug reaction
or adverse drug effect.
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Table 3. Three-level multiple linear regression models predicting medication adherence, intention, perceived behavioral control, automaticity of medication taking, self-monitoring, action, and coping planning
MARS
INT PBC SRBAI SM ACP CP
Variable Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value
Group (Ref: UC) 0.69 (0.61) 0.26 0.13 (0.13) 0.39 0.09 (0.18) 0.80 0.009 (0.15) 0.99 0.07 (0.15) 0.57 0.11 (0.13) 0.49 0.07 (0.12) 0.47
Time (Ref: baseline)
One month 0.38 (0.16) 0.018 0.09 (0.04) 0.02 0.06 (0.04) 0.13 0.02 (0.04) 0.62 0.04 (0.04) 0.31 0.03 (0.04) 0.45 0.03 (0.04) 0.45
Six months 0.25 (0.16) 0.12 0.02 (0.04) 0.56 0.06 (0.04) 0.13 0.07 (0.04) 0.05 0.06 (0.04) 0.16 0.05 (0.04) 0.29 0.04 (0.04) 0.29
Group × Time
EXP vs.UC at 1 month 3.15 (0.230) <0.001 0.64 (0.05) <0.001 0.59 (0.06) <0.001 0.45 (0.05) <0.001 0.55 (0.06) <0.001 0.76 (0.06) <0.001 0.77 (0.06) <0.001
EXP vs. UC at 6
months
3.20 (0.23) <0.001 0.60 (0.05) <0.001 0.59 (0.05) <0.001 0.43 (0.05) <0.001 0.50 (0.06) <0.001 0.78 (0.06) <0.001 0.78 (0.06) <0.001
Intercept 10.88 (2.15) <0.001 2.88 (0.38) <0.001 2.84 (0.46) <0.001 2.29 (0.43) <0.001 2.54 (0.32) <0.001 2.42 (0.39) <0.001 2.18 (0.388) <0.001
σˆ2st (patients) 1.91 (0.62) 0.003 0.11 (0.03) 0.002 0.20 (0.06) <0.001 0.13 (0.04) 0.002 0.15 (0.04) <0.001 0.08 (0.03) 0.007 0.09 (0.03) 0.003
σˆ2sc (centers) 15.16 (0.94) <0.001 0.41 (0.03) <0.001 0.61 (0.04) <0.001 0.57 (0.04) <0.001 0.21 (0.02) <0.001 0.42 (0.030) <0.001 0.42 (0.03) <0.001
Note. UC, usual care group; EXP, experimental group; MARS, Medication Adherence Rating Scale; INT, intention; PBC, Perceived behavioral control; SRBAI, Self-report Behavioral
Automaticity Index; SM, Self-monitoring; ACP, Action planning; CP, Coping planning; ADR, Adverse drug reaction.
Table 4. Three-level multiple linear regression models predicting beliefs about medication, Mania symptoms, severity of illness, depression, and quality of life
BMQ speciﬁc
necessity
BMQ speciﬁc
concerns YMRS CGI-BP-S MARDS QoL.BD ADR
Variable Β (S.E.) p value Β (S.E.) p value Β (S.E.) P value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value Β (S.E.) p value
Group (Ref: UC) 0.02 (0.58) 0.97 −0.20 (0.78) 0.80 −0.10 (0.44) 0.81 −0.08 (0.16) 0.62 −0.48 (1.26) 0.71 1.21 (1.07) 0.26 0.08 (0.11) 0.46
Time (Ref: baseline)
One month 0.07 (0.12) 0.59 −0.18 (0.19) 0.35 −0.02 (0.18) 0.91 0.01 (0.03) 0.81 −0.45 (0.23) 0.055 0.27 (0.37) 0.46 0.10 (0.07) 0.15
Six months 0.54 (0.12) <0.001 −0.24 (0.19) 0.21 −0.04 (0.01) <0.001 0.03 (0.03) 0.33 −0.60 (0.24) 0.012 0.031 (0.37) 0.93 0.16 (0.14) 0.25
Group × Time
EXP vs. UC at 1
month
4.51 (0.17) <0.001 −6.67 (0.27) <0.001 −3.1 (0.01) <0.001 −0.26 (0.05) <0.001 −4.70 (0.33) <0.001 0.93 (0.55) 0.09 0.14 (0.09) 0.12
EXP vs. UC at 6
months
4.83 (0.17) <0.001 −6.82 (0.28) <0.001 −5.39 (0.01) <0.001 −0.53 (0.05) <0.001 −4.54 (0.33) <0.001 1.40 (0.52) 0.025 0.20 (0.12) 0.09
Intercept 15.39 (1.31) <0.001 10.47 (1.72) <0.001 13.41 (1.34) <0.001 5.00 (0.373) <0.001 24.09 (2.69) <0.001 44.99 (4.54) <0.001 6.68 (0.33) <0.001
σˆ2st (patients) 2.25 (0.62) <0.001 4.12 (1.12) <0.001 1.20 (0.36) 0.002 0.165 (0.048) <0.001 10.88 (2.99) <0.001 3.92 (1.92) 0.051 0.512 (0.13) <0.001
σˆ2sc (centers) 4.63 (0.31) <0.001 7.18 (0.52) <0.001 6.35 (0.36) <0.001 0.384 (0.025) <0.001 19.36 (1.27) <0.001 71.19 (4.45) <0.001 0.42 (0.11) <0.001
Note. UC, usual care group; EXP, experimental group; BMQ, Beliefs about Medicines Questionnaire; YMRS, Young Mania Rating Scale; CGI-BP-S, Clinical Global
Impressions-Bipolar-Severity of Illness; MARDS, Montgomery Åsberg Depression Rating Scale; QoL.BD, Quality of Life in Bipolar Disorder scale; ADR, Adverse drug reaction.
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levels at 1 month (B = 2.46; S.E. = 0.36; p < 0.001) and 6
month (B = 2.59; S.E. = 0.49; p < 0.001) follow-ups, and
on improvements in Serum Sodium Valproate levels
at 1 month (B = 2.17; S.E. = 0.68; p < 0.001) and 6 month
(B = 1.92; S.E. = 0.62; p < 0.001) follow-ups.
Discussion
The aim of the present research was to assess the
efﬁcacy of a multifaceted intervention on MA and
health outcomes in patients with BD. We found that
a combination of brief sessions of MI, together with
psychoeducation and efforts to engage family mem-
bers in promoting adherence led to signiﬁcant
improvements in objective and self-report measures
of MA, as well as in various clinical and functional out-
comes compared with usual care. As such, we hope
that the ﬁndings are informative to mental health clin-
icians seeking to promote MA among patients with BD
and provide a rationale for designing and implement-
ing multifaceted interventions to improve MA in such
patients.
A few prior studies have investigated whether inter-
ventions based on MI can improve MA in patients with
BD. In a quasi-experimental pilot study of 21 elderly
subjects with BD, Depp et al. showed that a multifa-
ceted intervention, including motivational training
improved MA, as well as depressive symptoms and
QoL (Depp et al. 2007). However, this was only a pre-
liminary pilot study with a simple training interven-
tion and a limited outcome measure. Another study
on patients with BD in Iran, showed the effectiveness
of an intervention based on psychoeducation. This
study included an 18 month follow-up and measured
QoL, medication compliance as well as frequency of
hospitalization showing considerable improvements
in each outcome (Javadpour et al. 2013). However,
the study only involved one center with 108 patients
the intervention only used psychoeducation and did
not include family members.
In addition to MI, our intervention included other
components, namely psychoeducation and engage-
ment of a family member. We found promising effects
of the intervention on both self-reported and objective
measures of MA. Furthermore, our ﬁndings also
pointed to improvements in symptoms and QoL,
which mediation analyses indicated can be attributed
to improved MA.
Strengths and limitations
The present research had several strengths. First, we
used both self-report and objective outcome measures
to ensure the validity of our ﬁndings. Second, using
multiple outcome measures targeting different
domains allowed us to look at the effect of the inter-
vention on different aspects of health and functioning.
Third, we used a multilevel linear mixed model to
evaluate the effect of intervention on outcomes.
Our ﬁndings should be interpreted in light of some
limitations, however. First, family engagement consti-
tuted an important component of the intervention in
the present research. While we deem this to be a
strength of our multifaceted approach, we acknow-
ledge that family likely plays a more signiﬁcant role
in individuals who live in Middle Eastern cultures
than in other, more Western societies (Daneshpour,
1998). Therefore, the effect of the family component
of our intervention might not necessarily be generaliz-
able to other cultures. Second, we did not assess the
effect of our intervention beyond 6 months of
follow-up. However, a meta-analysis by MacDonald
and colleagues showed that the effects of interventions
on MA seemed to be durable for up to 2 years
(MacDonald et al. 2016). There is no reason to believe
that the effects of the present intervention might not
also be maintained over this period. Third, it might
be argued that a longer intervention might improve
adherence rates even further. However, the feasibility
of interventions should be considered in term of time
and cost as well as efﬁcacy as longer interventions
may require greater investment of resources for a rela-
tively small improvement in outcomes. Finally, a nat-
ural downside to a multifaceted approach to
intervention is that it is difﬁcult to isolate, which part
of the intervention was most effective. Future research
might usefully adopt factorial designs that systematic-
ally manipulate and compare different components of
the intervention (e.g. the intervention with and with-
out family support) in an effort to identify the active
ingredients.
Conclusion
The present ﬁndings provide robust evidence that a
multifaceted intervention based on MI, psychoeduca-
tion, and attempts to engage family members can
improve MA among patients with BD. The implication
is that healthcare professionals, especially those who
deal with mental health aspects of people with psychi-
atric disorders such as BD, may use our ﬁndings to
improve MA and adjust clinical symptoms in their
clients.
Supplementary material
The supplementary material for this article can be
found at https://doi.org/10.1017/S003329171700109X.
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